SANDRA CATLIN: Open Payments
NPI 1447205760 · FALLS CITY, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$847 in 51 payments from 12 companies in 2025. Trend: 2023 $651 · 2024 $716 · 2025 $847
Food & beverage: $847
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $251 |
| Otsuka America Pharmaceutical, Inc. | 10 | $170 |
| Novo Nordisk Inc | 5 | $108 |
| Neurocrine BioSciences, Inc. | 5 | $83 |
| Vanda Pharmaceuticals Inc. | 4 | $75 |
| Novartis Pharmaceuticals Corporation | 1 | $35 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Amgen Inc. | 2 | $27 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $17 |
Products named: VRAYLAR, Wegovy, ABILIFY ASIMTUFII, INGREZZA, REXULTI, HETLIOZ, QULIPTA, FANAPT.
Industry payments across NE — which companies pay providers there.
